ORAL MUCOSAL CHANGES AND NICOTINE DISPOSITION IN USERS OF SWEDISH SMOKELESS TOBACCO PRODUCTS - A COMPARATIVE-STUDY

被引:48
作者
ANDERSSON, G
BJORNBERG, G
CURVALL, M
机构
[1] RESERCA AB,S-11884 STOCKHOLM,SWEDEN
[2] LUND UNIV,DEPT ORAL SURG & ORAL MED,MALMO,SWEDEN
关键词
NICOTINE METABOLISM; TSNA; ORAL MANIFESTATIONS; SMOKELESS TOBACCO;
D O I
10.1111/j.1600-0714.1994.tb01106.x
中图分类号
R78 [口腔科学];
学科分类号
1003 [口腔医学];
摘要
The purpose of this study was to investigate the uptake and metabolism of nicotine by smokeless (oral) tobacco users and to find out if the less pronounced clinical changes in the oral mucosa in users of portion-bag packed oral moist snuff (snus) compared with the changes in the mucosa of loose snus users are correlated to exposure and uptake of tobacco constituents. 54 habitual users of smokeless tobacco were selected for the study: 22 loose snus users, 23 users of portion-bag packed snus and 9 users of chewing tobacco. In accordance with previous findings, less pronounced clinical changes in the oral mucosa were recorded in portion-bag users compared with loose anus users. The clinical findings observed in the oral mucosa of users of chewing tobacco were leukoedema and slight clinical ''snus changes''. The average intake of nicotine (measured as nicotine equivalents excreted during 24 h) for snus users was 35 mg, and was 50% higher for users of chewing tobacco. The average steady-state saliva cotinine concentration was about 300 ng/ml for both categories of snus users, which is similar to that found in smokers, while the average concentration found in users of chewing tobacco was 50% higher. There was a good correlation between saliva cotinine concentration and the 24 h intake of nicotine. The average excretion profile of nicotine was similar in all three groups of smokeless tobacco users, being on average: nicotine 8%, nicotine-GlcA 3%, cotinine 8%, cotinine-GlcA 9%, 3'-hydroxycotinine 42%, 3'hydroxycotinine-GlcA 19%, nicotine-N'-oxide 9% and cotinine-N-oxide 3%. The clinical severity of buccal mucosal changes correlated neither with the markers for exposure (i.e. nicotine and tobacco specific nitrosamines extracted from the tobacco) nor with the biological markers for uptake of tobacco constituents (i.e. nicotine equivalents excreted during 24 h and saliva cotinine concentrations).
引用
收藏
页码:161 / 167
页数:7
相关论文
共 26 条
[1]
ANDERSSON G, 1991, SWED DENT J S, V175
[2]
ANDERSSON G, 1989, J ORAL PATHOL MED, V17, P1
[3]
ABSORPTION AND METABOLISM OF NICOTINE FROM CIGARETTES [J].
ARMITAGE, AK ;
DOLLERY, CT ;
GEORGE, CF ;
HOUSEMAN, TH ;
LEWIS, PJ ;
TURNER, DM .
BRITISH MEDICAL JOURNAL, 1975, 4 (5992) :313-316
[4]
Axell T, 1992, J Dent Assoc S Afr, V47, P194
[5]
RELATION OF CLINICAL PICTURE TO HISTOPATHOLOGY OF SNUFF DIPPERS LESIONS IN A SWEDISH POPULATION [J].
AXELL, T ;
MORNSTAD, H ;
SUNDSTROM, B .
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 1976, 5 (04) :229-236
[6]
NICOTINE ABSORPTION AND CARDIOVASCULAR EFFECTS WITH SMOKELESS TOBACCO USE - COMPARISON WITH CIGARETTES AND NICOTINE GUM [J].
BENOWITZ, NL ;
PORCHET, H ;
SHEINER, L ;
JACOB, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (01) :23-28
[7]
CIRCADIAN BLOOD NICOTINE CONCENTRATIONS DURING CIGARETTE-SMOKING [J].
BENOWITZ, NL ;
KUYT, F ;
JACOB, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 32 (06) :758-764
[8]
DAILY INTAKE OF NICOTINE DURING CIGARETTE-SMOKING [J].
BENOWITZ, NL ;
JACOB, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (04) :499-504
[9]
DAILY USE OF SMOKELESS TOBACCO - SYSTEMIC EFFECTS [J].
BENOWITZ, NL ;
JACOB, P ;
YU, L .
ANNALS OF INTERNAL MEDICINE, 1989, 111 (02) :112-116
[10]
STABLE ISOTOPE STUDIES OF NICOTINE KINETICS AND BIOAVAILABILITY [J].
BENOWITZ, NL ;
JACOB, P ;
DENARO, C ;
JENKINS, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (03) :270-277